Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
GLYC's Cash to Debt is ranked higher than
82% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. GLYC: No Debt )
GLYC' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
GLYC's Interest Coverage is ranked higher than
86% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GLYC: No Debt )
GLYC' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 21.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -50.09
GLYC's Operating margin (%) is ranked higher than
75% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. GLYC: -50.09 )
GLYC' s 10-Year Operating margin (%) Range
Min: -265.19   Max: 24
Current: -50.09

-265.19
24
Net-margin (%) -50.11
GLYC's Net-margin (%) is ranked higher than
75% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. GLYC: -50.11 )
GLYC' s 10-Year Net-margin (%) Range
Min: -265.61   Max: 23.96
Current: -50.11

-265.61
23.96
ROE (%) -20.38
GLYC's ROE (%) is ranked higher than
78% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. GLYC: -20.38 )
GLYC' s 10-Year ROE (%) Range
Min: -137.43   Max: 34.84
Current: -20.38

-137.43
34.84
ROA (%) -18.72
GLYC's ROA (%) is ranked higher than
77% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. GLYC: -18.72 )
GLYC' s 10-Year ROA (%) Range
Min: -89.49   Max: 15.45
Current: -18.72

-89.49
15.45
ROC (Joel Greenblatt) (%) -1582.33
GLYC's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. GLYC: -1582.33 )
GLYC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1849.61   Max: 1623.95
Current: -1582.33

-1849.61
1623.95
» GLYC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

GLYC Guru Trades in

Q1 2014

GLYC Guru Trades in Q1 2014

Steven Cohen 28,648 sh (New)
» More
Q2 2014

GLYC Guru Trades in Q2 2014

George Soros 10,300 sh (New)
» More
Q3 2014

GLYC Guru Trades in Q3 2014

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GLYC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Sold Out $7.13 - $9.47 $ 9.113%0
George Soros 2014-06-30 New Buy$6.12 - $16.76 $ 9.1-9%10300
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.00
GLYC's P/B is ranked higher than
84% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. GLYC: 3.00 )
GLYC' s 10-Year P/B Range
Min: 1.81   Max: 3
Current: 3

1.81
3
EV-to-EBIT -14.84
GLYC's EV-to-EBIT is ranked higher than
82% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GLYC: -14.84 )
GLYC' s 10-Year EV-to-EBIT Range
Min: -26.2   Max: -12.5
Current: -14.84

-26.2
-12.5
Current Ratio 13.14
GLYC's Current Ratio is ranked higher than
91% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. GLYC: 13.14 )
GLYC' s 10-Year Current Ratio Range
Min: 2.14   Max: 21.83
Current: 13.14

2.14
21.83
Quick Ratio 13.14
GLYC's Quick Ratio is ranked higher than
92% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. GLYC: 13.14 )
GLYC' s 10-Year Quick Ratio Range
Min: 2.14   Max: 21.83
Current: 13.14

2.14
21.83

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.00
GLYC's Price/Net Cash is ranked higher than
94% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. GLYC: 3.00 )
GLYC' s 10-Year Price/Net Cash Range
Min: 2.32   Max: 5.65
Current: 3

2.32
5.65
Price/Net Current Asset Value 3.00
GLYC's Price/Net Current Asset Value is ranked higher than
94% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. GLYC: 3.00 )
GLYC' s 10-Year Price/Net Current Asset Value Range
Min: 2.32   Max: 5.65
Current: 3

2.32
5.65
Price/Tangible Book 3.00
GLYC's Price/Tangible Book is ranked higher than
88% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. GLYC: 3.00 )
GLYC' s 10-Year Price/Tangible Book Range
Min: 2.28   Max: 5.54
Current: 3

2.28
5.54
Price/Median PS Value 1.20
GLYC's Price/Median PS Value is ranked higher than
67% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. GLYC: 1.20 )
GLYC' s 10-Year Price/Median PS Value Range
Min: 0.98   Max: 0.98
Current: 1.2

Earnings Yield (Greenblatt) -6.80
GLYC's Earnings Yield (Greenblatt) is ranked higher than
67% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. GLYC: -6.80 )
GLYC' s 10-Year Earnings Yield (Greenblatt) Range
Min: -6.8   Max: 0
Current: -6.8

-6.8
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:GKO.Germany

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK